Jessica Scott, MD, JD, CEO of Legacy Health Strategies, will join an upcoming webinar panel hosted by the Multi-Regional Clinical Trials Center of Brigham and Women’s Hospital and Harvard (MRCT Center), focused on patient-centered approaches to Long-Term Follow-Up (LTFU) studies in Cell and Gene Therapy (C>).
Join us on Thursday, June 26, from 1–2 PM ET for this timely and important conversation moderated by Carolyn Chapman. The webinar will explore how to reduce the burden of extended follow-up while keeping patients at the center of every decision. These advanced therapies hold the promise of long-lasting, even curative results—but with that promise come unknowns, which is why regulatory agencies like the FDA and EMA require follow-up periods ranging from 5 to 15 years. These studies are essential, but they can be challenging and burdensome for patients. We’ll explore what it takes to make them more meaningful and sustainable.
The panel will feature three perspectives:
- George Eastwood, Executive Director of the Emily Whitehead Foundation, addressing the challenge of patient loss to follow-up in pediatric gene therapy.
- Tesha Samuels, founder of Journey to ExSCellence, sharing her lived experience with Sickle Cell Disease and advocating for more compassionate care.
- Jessica Scott, CEO of Legacy Health Strategies, offering insight into how to operationalize patient perspectives into C> LTFU strategies and implementation.
